Nanowires Create Elite Warriors to Enhance T Cell Therapy

Georgia Tech bioengineer Ankur Singh and his team have developed a method to enhance adoptive T-cell therapy using nanowires to deliver miRNA to T-cells, preserving their naïve state for more effective disease-fighting. This innovative technique allows the T-cells to remain programmable and robust, offering a potential gamechanger for immunotherapies.

MD Anderson Research Highlights for June 5, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Penn Medicine at the American Society of Gene and Cell Therapy 27th Annual Meeting

Researchers from the Gene Therapy Program (GTP) at the Perelman School of Medicine at the University of Pennsylvania will present ten research abstracts, two invited talks, and a workshop presentation highlighting their translational science and discovery research on gene therapy, gene editing, and adeno-associated virus (AAV) vector technology at the American Society of Cell and Gene Therapy (ASGCT) 27th Annual Meeting on May 7 – 11, 2024 in Baltimore, Maryland.

A gene mutation associated with a rare neurological disorder and increased susceptibility to viral infections may be treatable with oleic acid

A mutation in a protein regulating natural killer (NK) cells’ function is at the root of immune deficiency in some people with a rare genetic condition characterized by cognitive and developmental delay, seizures, and other manifestations. The findings also have broader implications for immunity and cell therapies.

Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects

Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. For diverse disease conditions, the currently available approaches are focused on alleviating clinical sympt

NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster

A team of researchers from the National University of Singapore has engineered an innovative magnetic wound-healing gel that promises to heal diabetic wounds three times faster, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

The innovative magnetic hydrogel, which contains skin cells for healing as well as magnetic particles, takes a comprehensive ‘all-in-one’ approach to wound healing, accelerating the process on several fronts. To maximise therapeutic results, a wireless external magnetic device is used to activate skin cells and accelerate the wound healing process. A patent has been filed for this innovation.

CHOP Researchers Identify Molecules that Optimize Immune Presentation of Antigens across the Human Population

Researchers at Children’s Hospital of Philadelphia (CHOP) have identified variants of a chaperone molecule that optimizes the binding and presentation of foreign antigens across the human population, which could open the door to numerous applications where robust presentation to the immune system is important, including cell therapy and immunization. The findings were published today in Science Advances.

CHOP Researchers Develop Tool that Reduces Errors in Stem Cell Transplant Reporting

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and at the same time substantially improves accuracy of reported hematopoietic cell transplant engraftments.

MD Anderson Research Highlights: ESMO 2022 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting

Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.

MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer

MD Anderson and Resilience today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, which unites the strengths of both parties to accelerate the development and manufacturing of cell therapies for patients with cancer.

MD Anderson Research Highlights: ESMO 2021 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.

MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.

Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.

Penn Medicine and Children’s Hospital of Philadelphia to Host Symposium on the Future of Cell and Gene Therapies

Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor, CAR, T cell therapy and more.

Tip Sheet: Diversity in vaccine clinical trials, behind-the-scenes look at COVID-19 biostats, new cell therapy approved, plus meet ‘Megasphaera hutchinsoni’

SEATTLE —  March 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.March is Women’s History month. We’d like to honor Dottie Thomas, known as the “mother of bone marrow transplantation.” She spent years working as a research partner alongside her husband, Nobel Prize-winning Dr.

Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel

SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.

Scientists Take Important Step Toward Using Retinal Cell Transplants to Treat Blindness

Retinal cells derived from a cadaver human eye survived when transplanted into the eyes of primate models, an important advance in the development of cell therapy to treat blindness, according to a study published on January 14 in Stem Cell Reports.

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.